Bliss GVS Pharma Ltd
Fri 30/05/2025,15:59:52 | NSE : BLISSGVS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 133.45
Previous Close
₹ 133.55
Volume
317110
Mkt Cap ( Rs. Cr)
₹1379.82
High
₹ 134.90
Low
₹ 130.00
52 Week High
₹ 185.50
52 Week Low
₹ 92.15
Book Value Per Share
₹ 95.85
Dividend Yield
0.38
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Bliss GVS Pharma Ltd
Your Vote -
Buy
84.38%
Hold
9.38%
Sell
6.25%
84.38%
32 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Bliss GVS Pharma Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Bliss GVS Pharma - Update On Legal Proceeding
-
Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
Bliss GVS Pharma - Copy of Newspaper Publication
-
Bliss GVS Pharma - Sale or disposal-XBRL
-
Bliss GVS Pharma - Alteration Of Capital and Fund Raising-XBRL
-
Bliss GVS Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Bliss GVS Pharma - Notice Of Shareholders Meetings-XBRL
-
Bliss GVS Pharma - Outcome of Board Meeting-XBRL
-
Bliss GVS Pharma - Copy of Newspaper Publication
-
Bliss GVS Pharma - Outcome of Board Meeting
-
Bliss GVS Pharma - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019
-
Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Change in Management
-
Bliss GVS Pharma - Options to purchase securities
-
Bliss GVS Pharma - Integrated Filing (Financial)
-
Bliss GVS Pharma - Change in Auditors
-
Bliss GVS Pharma posts Q4 net profit of Rs 11.45 cr
-
Bliss GVS Pharma - Updates
-
Bliss GVS Pharma - Dividend
-
Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Bliss GVS Pharma - Shareholders meeting
-
Bliss GVS Pharma - Intimation Of Book Closure In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Re
-
Bliss GVS Pharma - Corporate Action-Board approves Dividend
-
Bliss GVS Pharma - Outcome of Board Meeting
-
Bliss GVS Pharma - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 12, 2025.
-
Bliss GVS Pharma - Issue of Securities
-
Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Issue of Securities
-
Bliss GVS Pharma - Update on board meeting
-
Bliss GVS Pharma - Board Meeting Intimation
-
Bliss GVS Pharma - Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Comp
-
Bliss GVS Pharma - Board Meeting Intimation
-
Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
Bliss GVS Pharma - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015- Pendency Of Litigation(S)/Dispute(S)\r\n
-
Bliss GVS Pharma - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Bliss GVS Pharma - Intimation Of Change In Contact Details Of MUFG Intime India Private Limited, Registrar And Share Transfer
-
Bliss GVS Pharma - Updates
-
Bliss GVS Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Bliss GVS Pharma - Updates
-
Bliss GVS Pharma - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015.
-
Bliss GVS Pharma - Pendency Of Litigation(S)/Dispute(S)
-
Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
Bliss GVS Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Bliss GVS Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Change in Management
-
Bliss GVS Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Bliss GVS Pharma - Change in Management
-
Bliss GVS Pharma - Trading Window-XBRL
-
Bliss GVS Pharma - Trading Window
-
Bliss GVS approves to increase FII investment limit
-
Bliss GVS board to consider disinvestment; stk up
Key fundamentals
Evaluate the intrinsic value of Bliss GVS Pharma Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 1109.642 | 1054.0754 | 1014.0767 | 937.0434 | 823.5159 |
| Liabilities | 1109.642 | 1054.0754 | 1014.0767 | 937.0434 | 823.5159 |
| Equity | 10.537 | 10.4691 | 10.4153 | 10.3678 | 10.3147 |
| Gross Profit | 91.5856 | 107.1687 | 90.1552 | 109.199 | 91.4603 |
| Net Profit | 68.9687 | 50.6449 | 85.4786 | 92.664 | 67.5008 |
| Cash From Operating Activities | 97.2054 | 125.9225 | 43.8057 | 114.0494 | 66.9672 |
| NPM(%) | 10.33 | 8.36 | 14.28 | 14.56 | 14.5 |
| Revenue | 667.2046 | 605.4597 | 598.3395 | 636.3567 | 465.5131 |
| Expenses | 575.619 | 498.291 | 508.1843 | 527.1577 | 374.0528 |
| ROE(%) | 6.82 | 5.01 | 8.46 | 9.17 | 6.68 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 0.5 | 50 | 0.38 | 118.77 | |
| 18 Jul 2024 | 0.5 | 50 | 0.38 | 119.05 |
| 12 Jul 2023 | 0.5 | 50 | 0.38 | 83.8 |
| 20 Jun 2022 | 0.5 | 50 | 0.38 | 79 |
| 13 Sep 2021 | 0.5 | 50 | 0.38 | 128.1 |
| 17 Sep 2020 | 0.5 | 50 | 0.38 | 102.35 |
| 1 | 100 | 0.38 | 173.6 | |
| 14 Aug 2018 | 1 | 100 | 0.38 | 196.65 |
| 18 Sep 2017 | 0.6 | 60 | 0.38 | 177.2 |
| 0.5 | 50 | 0.38 | 95.2 | |
| 08 Sep 2015 | 0.5 | 50 | 0.38 | 122.45 |
| 24 Feb 2015 | 0.2 | 20 | 0.38 | 110.9 |
| 13 Aug 2014 | 0.5 | 50 | 0.38 | 43.8 |
| 01 Aug 2013 | 0.4 | 40 | 0.38 | 28.6 |
| 25 Feb 2013 | 0.3 | 30 | 0.38 | 36.5 |
| 02 Aug 2012 | 0.4 | 40 | 0.38 | 23 |
| 24 Nov 2011 | 0.35 | 35 | 0.38 | 23.7 |
| 14 Jul 2011 | 0.3 | 30 | 0.38 | 22.5 |
| 25 Nov 2010 | 0.3 | 30 | 0.38 | 44.75 |
Peers
Other companies within the same industry or sector that are comparable to Bliss GVS Pharma Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 802.25 | -0.44 | 26.62 | 74.82 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 71.90 | -0.18 | 205.43 | 272.64 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 12.69 | -0.16 | 211.50 | 140.53 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 672.20 | -0.91 | 0.00 | 257.08 | -687.10 | 0.00 |
Company Info
1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.
1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.
Read More
Parent Organisation
Bliss GVS Pharma Ltd.
Founded
11/12/1984
Managing Director
Mr.Gagan Harsh Sharma
NSE Symbol
BLISSGVSEQ
FAQ
The current price of Bliss GVS Pharma Ltd is ₹ 130.95.
The 52-week high for Bliss GVS Pharma Ltd is ₹ 134.90 and the 52-week low is ₹ 130.00.
The market capitalization of Bliss GVS Pharma Ltd is currently ₹ 1379.82. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Bliss GVS Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Bliss GVS Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Bliss GVS Pharma Ltd shares.
The CEO of Bliss GVS Pharma Ltd is Mr.Gagan Harsh Sharma, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
